GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » Cash Ratio

Novo Integrated Sciences (Novo Integrated Sciences) Cash Ratio : 0.07 (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Novo Integrated Sciences's Cash Ratio for the quarter that ended in Feb. 2024 was 0.07.

Novo Integrated Sciences has a Cash Ratio of 0.07. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Novo Integrated Sciences's Cash Ratio or its related term are showing as below:

NVOS' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.46   Max: 4.33
Current: 0.07

During the past 13 years, Novo Integrated Sciences's highest Cash Ratio was 4.33. The lowest was 0.01. And the median was 0.46.

NVOS's Cash Ratio is ranked worse than
89.02% of 656 companies
in the Healthcare Providers & Services industry
Industry Median: 0.5 vs NVOS: 0.07

Novo Integrated Sciences Cash Ratio Historical Data

The historical data trend for Novo Integrated Sciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences Cash Ratio Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.80 0.98 0.15 0.05

Novo Integrated Sciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.07 0.05 0.15 0.07

Competitive Comparison of Novo Integrated Sciences's Cash Ratio

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Integrated Sciences's Cash Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Cash Ratio falls into.



Novo Integrated Sciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Novo Integrated Sciences's Cash Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash Ratio (A: Aug. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.416/7.905
=0.05

Novo Integrated Sciences's Cash Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash Ratio (Q: Feb. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.652/9.959
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Integrated Sciences  (NAS:NVOS) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Novo Integrated Sciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
Executives
Sarfaraz Ali director C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva director 115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope director 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias director 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor director 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione director, 10 percent owner, officer: Chief Executive Officer 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt director, 10 percent owner 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David director, officer: President 10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald officer: Chief Accounting Officer 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters director 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse officer: secretary 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden officer: President & CEO 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo director 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724